Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

New research could help engineer crops that recover after extreme weather eventsPlants pause their growth during stress, then press play when ...

Using CDK4/6 inhibitors as first-line therapy in advanced breast cancer does not improve overall survival compared with ...

Plants pause their growth during stress, then press play when conditions improve, helping them recover and live on to produce food, according to a new study published in New Phytologist. UBC ...

Roche Holdings AG on Monday shared results from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients. Trial Misses Primary Goal The trial ...

Roche’s phase III persevERA Breast Cancer study of giredestrant in combo with palbociclib ER-positive advanced breast cancer fails to meet its primary objective: Basel Tuesday, ...

In the study, giredestrant showed no statistical improvement in the primary endpoint, but there was a numerical improvement.

persevERA is the first of two distinct Phase III studies in the first-line setting; the pionERA study of giredestrant in combination with physician’s choice of cyclin-dependent kinase (CDK)4/6 ...

The study did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a ...